144 related articles for article (PubMed ID: 36870985)
1. Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report.
He J; Chen X; Cheng K; Lv W; Cao D; Li Z
BMC Neurol; 2023 Mar; 23(1):96. PubMed ID: 36870985
[TBL] [Abstract][Full Text] [Related]
2. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
3. Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Li S; Peng Y; Li J; Guo F; Yi C; Cao D
Front Immunol; 2020; 11():1127. PubMed ID: 32636837
[No Abstract] [Full Text] [Related]
4. Long-Term Survival of FOLFIRINOX +toripalimab in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma: A Case Report.
Jiang T; Gao C; Luo Y; Ye Z; Wang B
Onco Targets Ther; 2022; 15():883-890. PubMed ID: 36046467
[TBL] [Abstract][Full Text] [Related]
5. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
6. Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab.
Zhou H; Xie X; Zhang T; Yang M; Zhou D; Yang T
Front Immunol; 2022; 13():850540. PubMed ID: 35401563
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis.
Luo C; Chen H; Wu H; Liu Y; Li G; Lun W
Front Immunol; 2023; 14():1298902. PubMed ID: 38077371
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Bendell J; Sharma S; Patel MR; Windsor KS; Wainberg ZA; Gordon M; Chaves J; Berlin J; Brachmann CB; Zavodovskaya M; Liu J; Thai D; Bhargava P; Shah MA; Khan SA; Starodub A
Oncologist; 2020 Nov; 25(11):954-962. PubMed ID: 32812320
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
[TBL] [Abstract][Full Text] [Related]
10. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
11. PD-1-induced encephalopathy: a report of 2 cases on neurological toxicities with immune checkpoint inhibitors.
Chen X; Ye M; Ai R; Shan C; Lai M; Hong W; Yang Y; Wang H; Li J; Zhen J; Zhou J; Hu Q; Li S; Rossi A; Hida T; Rosell R; Zhong S; Cai L
Transl Cancer Res; 2024 Feb; 13(2):1196-1207. PubMed ID: 38482411
[TBL] [Abstract][Full Text] [Related]
12. Multisystem immune-related adverse events due to toripalimab: Two cases-based review.
Chen Y; Chen Y; Xie J; Liu D; Hong X
Front Cardiovasc Med; 2022; 9():1036603. PubMed ID: 36505392
[TBL] [Abstract][Full Text] [Related]
13. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
[TBL] [Abstract][Full Text] [Related]
14. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
[TBL] [Abstract][Full Text] [Related]
15. Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma.
Lin J; Xue M; Gao M; Yu P; Han S
Dermatol Ther (Heidelb); 2020 Aug; 10(4):863-867. PubMed ID: 32445174
[TBL] [Abstract][Full Text] [Related]
16. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
Kaneko T; Sugimori K; Tozuka Y; Fukushima T; Okada K; Oka H; Okazaki H; Maeda S
Clin J Gastroenterol; 2019 Oct; 12(5):484-489. PubMed ID: 30993653
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Tempero M; Oh DY; Tabernero J; Reni M; Van Cutsem E; Hendifar A; Waldschmidt DT; Starling N; Bachet JB; Chang HM; Maurel J; Garcia-Carbonero R; Lonardi S; Coussens LM; Fong L; Tsao LC; Cole G; James D; Macarulla T
Ann Oncol; 2021 May; 32(5):600-608. PubMed ID: 33539945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]